In line with these findings, clinical data showed that COPD patients with a higher IL-17A gene signature have a lower response to ICS therapy with respect to the change in FEV1%-predicted-over-30-months10. The gene discussed is IL17A; the disease is chronic obstructive pulmonary disease.